Lilly's Zepbound enhances Taltz efficacy in psoriasis study

A study has shown that the efficacy of Lilly's psoriasis therapy Taltz is improved when it is given in combination with weight-loss drug Zepbound.

AbbVie’s Skyrizi hits the spot in refractory psoriasis

Antibody works when IL-17 inhibitors Like Novartis' Cosentyx and Lilly's Taltz fail.

Lilly raises 2020 earnings forecast on pandemic stockpiling

Novartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthrit...

Lilly dips as biomed chief Christi Shaw heads to Gilead

Lilly’s Taltz scrapes win against Humira in psoriatic arthri...

Eli Lilly’s Taltz has beaten AbbVie’s blockbuster Humira in a psoriatic arthritis study involving patients who hadn’t been treated before with a disease-modifying drug, but only just.